The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.451%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 222.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Puretech Health proposes $100m capital return

Tue, 19th Mar 2024 09:46

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

PureTech said on Tuesday that the proposed capital return represented approximately 14% of its market capitalisation based on Monday's closing price and noted that it follows a previous announcement that it will receive approximately $293.0m in gross proceeds from its remaining stake in Karuna.

The AIM-listed group said the offer will be launched after the publication of its full-year results in April, subject to market conditions, and will require shareholder approval.

PureTech added that if the full $100.0m was not returned, then it intends to return any remainder following the completion of the offer, by way of a special dividend.

Chief executive Daphne Zohar said: "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14.0bn is a testament to our execution on both fronts. We directed $18.5m to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1bn in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years.

"We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50.0m share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

As of 1055 GMT, PureTech shares were up 8.58% at 221.50p.

Reporting by Iain Gilbert at Sharecast.com

More News
13 Apr 2022 18:47

TRADING UPDATES: BlueRock output rises; Watkin Jones profit to fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
12 Apr 2022 21:51

TRADING UPDATES: Gore Street fundraise; Pathfinder mulls disposal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Mar 2022 20:38

TRADING UPDATES: Angle US lab boost; Corcel to capitalise on nickel

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
4 Feb 2022 14:51

IN BRIEF: PureTech Health operations chief buys GBP50,000 in shares

IN BRIEF: PureTech Health operations chief buys GBP50,000 in shares

Read more
4 Feb 2022 09:34

LONDON BROKER RATINGS: Goldman starts Ceres at Sell, ITM at Neutral

LONDON BROKER RATINGS: Goldman starts Ceres at Sell, ITM at Neutral

Read more
14 Jan 2022 09:45

PureTech entity Gelesis starts trading on New York Stock Exchange

PureTech entity Gelesis starts trading on New York Stock Exchange

Read more
6 Jan 2022 17:59

IN BRIEF: PureTech Health reveals robust results from LYT-100 test

IN BRIEF: PureTech Health reveals robust results from LYT-100 test

Read more
20 Dec 2021 16:20

DIRECTOR DEALINGS: Micro Focus chair and new CFO buy shares

DIRECTOR DEALINGS: Micro Focus chair and new CFO buy shares

Read more
7 Dec 2021 09:32

LONDON BROKER RATINGS: Deutsche Bank raises NatWest, cuts Barclays

LONDON BROKER RATINGS: Deutsche Bank raises NatWest, cuts Barclays

Read more
1 Dec 2021 21:43

TRADING UPDATES: Honye Financial loss widens; Highway loss narrows

TRADING UPDATES: Honye Financial loss widens; Highway loss narrows

Read more
18 Nov 2021 22:03

TRADING UPDATES: FW Thorpe "up and down"; GB Group ties up US merger

TRADING UPDATES: FW Thorpe "up and down"; GB Group ties up US merger

Read more
16 Nov 2021 14:31

IN BRIEF: PureTech Health reaffirms LYT-100 positive trial results

IN BRIEF: PureTech Health reaffirms LYT-100 positive trial results

Read more
10 Nov 2021 18:22

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

Read more
10 Nov 2021 09:15

Puretech Health receives $100m from sale of 55% stake in Karuna Therapeutics

(Sharecast News) - Biotechnology company Puretech Health has received approximately $100.0m in cash from the sale of a portion of the group's shares in its founded entity Karuna Therapeutics.

Read more
9 Nov 2021 19:18

TRADING UPDATES: Sealand's China progress; Altus finds gold

TRADING UPDATES: Sealand's China progress; Altus finds gold

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.